Yeda Research and Develpment & Co. Ltd

Harvard College

Leland Stanford Junior University

Yeda Research and Development Ltd.

Veda Research and Development Co., Ltd.

Dvora Teitelbaum

Ruth Arnon

Michael Sela

Eliezer Konfino

Rina Aharoni

Jack L Strominger

Masha Fridkis-Hareli

Adrian Gilbert

Milka Linenberg

Rivka Riven-Kreitmann

Nelson J Chao

Paul G Schlegel

The present invention relates to an improved composition of copolymer-1 comprising copolymer-1 substantially free of species having a molecular weight of over 40 kilodaltons.

Copolymer-1 improvements in compositions of copolymers

The present invention is directed to polypeptides containing at least three amino acids randomly joined in a linear array; wherein at least one of the three amino acids is an aromatic amino acid, at least one of the three amino acids is a charged amino acid and at least one amino acid is an aliphatic amino acid. In a preferred embodiment the polypeptide contains three or four of the following amino acids: tyrosine, alanine, glutamic acid or lysine. According to the present invention, the present polypeptides bind to antigen presenting cells, purified human lymphocyte antigens (HLA) and/or Copolymer 1-specific T cells. Moreover, according to the present invention, these polypeptides can be formulated into pharmaceutical compositions for treating autoimmune disease. The present invention further contemplates methods of treating an autoimmune disease in a mammal by administering a pharmaceutically effective amount of any one of the present polypeptides to the mammal.

Treatment of autoimmune conditions with Copolymer 1 and related Copolymers

The present invention provides heteropolymer compositions and peptide compositions, and methods of making and using therapeutic compositions comprising amino acid heteropolymers for treatment of a subject for an autoimmune or an inflammatory disease, the heteropolymer compositions made by solid state synthesis. The invention also provides kits for assaying binding of a composition to a water-soluble MHC protein.

Treatment of autoimmune conditions with copolymer 1 and related copolymers

Compositions and methods for treating and preventing host-versus-graft disease and graft-versus-host disease comprising as active ingredient random copolymers of amino acids comprising one amino acid from at least three of the following groups: (a) lysine and arginine; (b) glutamic acid and aspartic acid; (c) alanine and glycine; and (d) tyrosine and tryptophan; with the proviso that the random copolymer is not Copolymer 1 or D-Copolymer 1 when the disease being treated is graft-versus-host disease.

Pharmaceutical compositions comprising synthetic peptide copolymers and methods for preventing and treating GVHD and HVGD

Copolymer-1 improvements on compositions of copolymers

The present invention relates to the treatment of multiple sclerosis by ingestion or inhalation of copolymet-1 and pharmaceutical compositions useful for such treatment.

Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1

Pharmaceutical compositions comprising as active ingredient a synthetic random copolymer of average molecular weight of about 4,000-12,000, preferably 6,000-8,000, said copolymer consisting of glutamic acid (Glu), lysine (Lys), alanine (Ala) and tyrosine (Tyr) residues in a relative molar ratio of 1.4-2.1 parts of Glu to 3.2-4.4 parts of Lys to 4.0-6.0 parts of Ala to 1.0 parts of Tyr (herein GLAT copolymers), can be used in a method for prevention and treatment of graft-versus-host disease in patients in the course of bone marrow and organ transplantation.

Pharmaceutical compositions comprising synthetic peptide copolymer for

Growing community of inventors

Rehovot, Israel

Dvora Teitelbaum